Bristol-Myers’ Rosy Outlook Trumps Trial Setback as Stock Gains

Bristol-Myers Squibb Co. acknowledged that its top-selling cancer drug faces challenges in coming years, one day after reporting a clinical setback that caused the drugmaker’s shares to fall.

Still, a rosier outlook for the rest of the year and a strong second quarter were enough to ease investors’ concerns, at least for now.